MXPA03010691A - Medicamentos combinado para tratamiento contra enfermedades neoplasticas. - Google Patents
Medicamentos combinado para tratamiento contra enfermedades neoplasticas.Info
- Publication number
- MXPA03010691A MXPA03010691A MXPA03010691A MXPA03010691A MXPA03010691A MX PA03010691 A MXPA03010691 A MX PA03010691A MX PA03010691 A MXPA03010691 A MX PA03010691A MX PA03010691 A MXPA03010691 A MX PA03010691A MX PA03010691 A MXPA03010691 A MX PA03010691A
- Authority
- MX
- Mexico
- Prior art keywords
- 4alkoxy
- amino
- 4alkyl
- sulfo
- trifluoromethyl
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 230000001613 neoplastic effect Effects 0.000 title 1
- -1 nitro, sulfo, cyano, amino Chemical group 0.000 abstract 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 229940041181 antineoplastic drug Drugs 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 abstract 1
- 239000004215 Carbon black (E152) Substances 0.000 abstract 1
- 239000003458 I kappa b kinase inhibitor Substances 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000005518 carboxamido group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- QGBSISYHAICWAH-UHFFFAOYSA-N dicyandiamide Chemical compound NC(N)=NC#N QGBSISYHAICWAH-UHFFFAOYSA-N 0.000 abstract 1
- 229930195733 hydrocarbon Natural products 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29292801P | 2001-05-24 | 2001-05-24 | |
| PCT/DK2002/000351 WO2002094322A2 (en) | 2001-05-24 | 2002-05-24 | Combination medicament for treatment of neoplastic diseases containing cyanoguanidine ikk inhibitors and a second anti-neoplastic drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA03010691A true MXPA03010691A (es) | 2004-07-01 |
Family
ID=23126850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA03010691A MXPA03010691A (es) | 2001-05-24 | 2002-05-24 | Medicamentos combinado para tratamiento contra enfermedades neoplasticas. |
Country Status (17)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7253193B2 (en) * | 2002-05-17 | 2007-08-07 | Leo Pharma A/S | Cyanoguanidine prodrugs |
| EP1507759A1 (en) * | 2002-05-17 | 2005-02-23 | Leo Pharma A/S | Cyanoguanidine produgs |
| PL228742B1 (pl) * | 2002-05-17 | 2018-05-30 | Leo Pharma As | Proleki cyjanoguanidynowe, kompozycja farmaceutyczna zawierająca te proleki oraz związki pośrednie |
| EP1556053A4 (en) | 2002-10-31 | 2006-04-19 | Amgen Inc | ANTI-INFLAMMATORY AGENTS |
| US20050101576A1 (en) * | 2003-11-06 | 2005-05-12 | Novacea, Inc. | Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes |
| WO2004047673A2 (en) * | 2002-11-21 | 2004-06-10 | Novacea, Inc. | Treatment of liver disease with active vitamin d compounds |
| US20050075341A1 (en) * | 2003-07-17 | 2005-04-07 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and an IKK inhibitor for the treatment of ischemic mediated central nervous system disorders or injury |
| PE20060373A1 (es) | 2004-06-24 | 2006-04-29 | Smithkline Beecham Corp | Derivados 3-piperidinil-7-carboxamida-indazol como inhibidores de la actividad cinasa de ikk2 |
| TW200626142A (en) | 2004-09-21 | 2006-08-01 | Glaxo Group Ltd | Chemical compounds |
| CA2594508C (en) | 2004-12-22 | 2013-10-01 | Leo Pharma A/S | Cyanoguanidine compounds |
| US8063071B2 (en) | 2007-10-31 | 2011-11-22 | GlaxoSmithKline, LLC | Chemical compounds |
| TWI380973B (zh) | 2005-06-30 | 2013-01-01 | Smithkline Beecham Corp | 化合物 |
| EP1912646A2 (de) * | 2005-08-04 | 2008-04-23 | Bayer HealthCare AG | KOMBINATIONEN MIT IKK-ß INHIBITOREN |
| AR065804A1 (es) | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento |
| KR20160029870A (ko) | 2008-04-21 | 2016-03-15 | 오토노미, 인코포레이티드 | 귀 질환 및 병태를 치료하기 위한 귀 조제물 |
| US11969501B2 (en) | 2008-04-21 | 2024-04-30 | Dompé Farmaceutici S.P.A. | Auris formulations for treating otic diseases and conditions |
| JP5580339B2 (ja) * | 2009-02-06 | 2014-08-27 | ティエンジン ホーメイ バイオ−テック カンパニー， リミテッド | ピリジルシアノグアニジンを含む薬物組成物、該組成物の製造方法及び応用 |
| WO2010102968A1 (en) | 2009-03-10 | 2010-09-16 | Glaxo Group Limited | Indole derivatives as ikk2 inhibitors |
| AR082886A1 (es) | 2010-09-03 | 2013-01-16 | Forma Therapeutics Inc | Compuestos y composiciones farmaceuticas que los contienen |
| AU2016281646A1 (en) * | 2015-06-23 | 2018-02-01 | Case Western Reserve University | Compositions and methods for treating cancer |
| CN109689027A (zh) | 2016-06-29 | 2019-04-26 | 奥德纳米有限公司 | 甘油三酯耳用制剂及其用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9219472D0 (en) * | 1992-09-15 | 1992-10-28 | Leo Pharm Prod Ltd | Chemical compounds |
| US5919816A (en) * | 1994-11-14 | 1999-07-06 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
| AU714618B2 (en) * | 1996-07-15 | 2000-01-06 | Sankyo Company Limited | Medicinal composition |
| GB9711124D0 (en) * | 1997-05-29 | 1997-07-23 | Leo Pharm Prod Ltd | Novel cyanoguanidines |
| GB9711122D0 (en) * | 1997-05-29 | 1997-07-23 | Leo Pharm Prod Ltd | Novel cyanoguanidines |
| GB9711125D0 (en) * | 1997-05-29 | 1997-07-23 | Leo Pharm Prod Ltd | Novel cyanoguanidines |
| GB9711123D0 (en) * | 1997-05-29 | 1997-07-23 | Leo Pharm Prod Ltd | Novel cyanoguanidines |
| GB9711119D0 (en) * | 1997-05-29 | 1997-07-23 | Leo Pharm Prod Ltd | Novel cyanoguanidines |
| AU1494702A (en) * | 2000-11-21 | 2002-06-03 | Leo Pharma As | Cyanoguanidine prodrugs |
-
2002
- 2002-05-21 US US10/151,094 patent/US20030045515A1/en not_active Abandoned
- 2002-05-24 CN CNA028121880A patent/CN1516600A/zh active Pending
- 2002-05-24 HU HU0400024A patent/HUP0400024A3/hu unknown
- 2002-05-24 JP JP2002591038A patent/JP2005508857A/ja not_active Withdrawn
- 2002-05-24 BR BR0209936-5A patent/BR0209936A/pt not_active IP Right Cessation
- 2002-05-24 AT AT02745167T patent/ATE394100T1/de not_active IP Right Cessation
- 2002-05-24 IL IL15882102A patent/IL158821A0/xx unknown
- 2002-05-24 RU RU2003137006/15A patent/RU2291710C2/ru not_active IP Right Cessation
- 2002-05-24 AU AU2002316795A patent/AU2002316795B2/en not_active Ceased
- 2002-05-24 CZ CZ20033189A patent/CZ20033189A3/cs unknown
- 2002-05-24 KR KR10-2003-7015363A patent/KR20040007607A/ko not_active Ceased
- 2002-05-24 DE DE60226446T patent/DE60226446D1/de not_active Expired - Fee Related
- 2002-05-24 EP EP02745167A patent/EP1411984B1/en not_active Expired - Lifetime
- 2002-05-24 MX MXPA03010691A patent/MXPA03010691A/es unknown
- 2002-05-24 PL PL02366462A patent/PL366462A1/xx not_active Application Discontinuation
- 2002-05-24 CA CA002449442A patent/CA2449442A1/en not_active Abandoned
- 2002-05-24 WO PCT/DK2002/000351 patent/WO2002094322A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005508857A (ja) | 2005-04-07 |
| WO2002094322A2 (en) | 2002-11-28 |
| CN1516600A (zh) | 2004-07-28 |
| EP1411984A2 (en) | 2004-04-28 |
| WO2002094322A3 (en) | 2004-02-26 |
| RU2003137006A (ru) | 2005-04-10 |
| CA2449442A1 (en) | 2002-11-28 |
| PL366462A1 (en) | 2005-02-07 |
| US20030045515A1 (en) | 2003-03-06 |
| EP1411984B1 (en) | 2008-05-07 |
| HUP0400024A3 (en) | 2007-05-29 |
| AU2002316795B2 (en) | 2007-08-02 |
| BR0209936A (pt) | 2004-04-06 |
| HUP0400024A2 (hu) | 2004-04-28 |
| DE60226446D1 (de) | 2008-06-19 |
| CZ20033189A3 (cs) | 2004-12-15 |
| ATE394100T1 (de) | 2008-05-15 |
| IL158821A0 (en) | 2004-05-12 |
| RU2291710C2 (ru) | 2007-01-20 |
| KR20040007607A (ko) | 2004-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA03010691A (es) | Medicamentos combinado para tratamiento contra enfermedades neoplasticas. | |
| CA2334713A1 (en) | Therapeutic biaryl derivatives | |
| AR049662A1 (es) | Derivados de 1,3-fenilendiamina con efecto inhibitorio de b-raf; un metodo para su preparacion, composiciones farmaceuticas que los contienen y su utilizacion en la fabricacion de medicamentos para el tratamiento del cancer | |
| AR039257A1 (es) | Derivados de benzamida | |
| TR200001279T2 (tr) | Poli (ADP-riboz) polimeraz ("PARP") inhibitörleri, nevral ve kardiyovasküler doku hasarının tedavisi için yöntemler ve farmasötik bileşimler. | |
| PT1341533E (pt) | Combinacoes sinergisticas compreendendo um inibidor de renina para doencas cardiovasculares | |
| GEP20053692B (en) | Substituted Alkylamine Derivatives and Methods of Use | |
| AU7453498A (en) | Sulfonamide derivatives, their production and use | |
| AR053992A1 (es) | Compuestos quimicos con actividad anticancerosa, un procedimiento para su preparacion, su uso en la preparacion de medicamentos y composicion farmaceutica. | |
| BR9813767A (pt) | Processo e composição para tratar glaucoma de glc1a | |
| EA200200306A1 (ru) | Трициклические ингибиторы поли(адф-рибозо)полимераз | |
| DE69633628D1 (de) | Dihydropyran-derivate als inhibitoren viraler neuramidase | |
| DK0723544T3 (da) | Alkoxyalkylcarbamater af imidazo[1,2-a]pyridiner | |
| GB9305295D0 (en) | Therapeutic compounds | |
| ATE206116T1 (de) | 6-carboxamido-dihydropyran-derivate | |
| DK0954305T3 (da) | Anvendelse af carbonanhydraseinhibitorer til behandling af maculaødem | |
| ES2185153T3 (es) | Uso de mefloquina(+) para el tratamiento de la malaria. | |
| WO2004014906A3 (en) | Nitro and amino substituted dibenzonaphthyridines as topoisomerase agents | |
| WO2004075858A3 (en) | Flavone acetic acid analogs and methods of use thereof | |
| GEP20063754B (en) | Quinoline Derivatives and Use Thereof as Antitumor Agents | |
| MX9700624A (es) | Azolidinonas de imidazopiridina. | |
| CA2432432A1 (en) | Use of (r)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs | |
| EP0466944A4 (en) | 4h-3,1-benzoxazin-4-one compound and elastase inhibitor composition containing the same | |
| BR0214104A (pt) | Oligopeptìdeos e composições contendo os mesmos como inibidores de catepsina | |
| CA2362697A1 (en) | Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ols, method for producing them and their use as medicaments |